Dose intensity has been related to clinical outcome in several solid tumors. We studied the influence of clinical and cellular parameters on dose intensity received in a series of 53 patients with metastatic breast cancer or advanced ovarian cancer. They received courses of cisplatin 120 mg/m2 plus etoposide 600 mg/m2 alternating every 14 days with ifosfamide 8 g/m2 plus paclitaxel 200–350 mg/m2. Blood stem cell support was administered after every course except for the first one. Patients with excellent mobilization underwent immunomagnetic selection of CD34+ cells. We found a significant inverse correlation between the CD34+ cell dose infused and the delay for the administration of the next cycle. A CD34+ cell dose between 1.5 and 5 × 106/kg per cycle was found to be feasible and was followed by a median delay of 1day (not different from doses above 5 × 106/kg). Three factors independently predicted the actually received dose intensity in a multiple regression model (R2 = 0.4): previous autologous transplantation, eligibility for immunomagnetic selection (excellent response to mobilization) and median CD34+ cell dose received along the treatment.

Keywords:
Dose intensity, Dose intensive, CD34, Stem cell, Breast cancer, Ovarian cancer, Cellular support, Positive selection, Purging
1.
Hryniuk W, Bush H: The importance of dose-intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984;2:1281–1288.
2.
Frei III E, Elias A, Wheeler C, Richardson P, Hryniuk W: Ther relationship bettween high-dose treastment and combination chemotherapy: The concept of summation dose intensity. Clin Cancer Res 1998;4:2027–2037.
3.
Hryniuk W, Frei III E, Wright FA: A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: Summation dose intensity. J Clin Oncol 1998;16:3137–3147.
4.
Hortobagyi GN, Hryniuk WH, Frye D, Gremm J, Buzdar AU: Dose-intensity analysis of high-dose chemotherapy for metastatic breast cancer. Proc Am Assoc Cancer Res 1989;30:252.
5.
Shapiro, Ayash L, Webb IJ, Gelman R, Keating J, Williams L, Demetri G, Clark P, Elias A, Duggan D, Hayes D, Hurd D, Henderson IC: Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol 1997;15:674–683.
6.
Viens P, Gravis G, Genre D, Bertucci F, Cowen D, Camerlo J, Cappiello MA, Conte M, Finaud M, Chabannon C, Houvenaeghel G, Maraninchi D: High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Bone Marrow Transplant 1997;3:199–203.
7.
Basser RL, To LB, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner CA, Russell I, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD: Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: Five-year follow-up. J Clin Oncol 1999;17:82–92.
8.
Crown J, Wassherheit C, Hakes T, Fennelly D, Reich L, Moore M, Schneider J, Curtin J, Rubin SC, Reichman B: Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells (letter). J Natl Cancer Inst 1992;16:1935–1936.
9.
Fennelly D, Schneider J, Spriggs D, Bengala C, Hakes T, Reich L, Barakat R, Curtin J, Moore MA, Hoskins W, Norton L, Crown J: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 1995;13:1160–1166.
10.
Aghajanian C, Fennelly D, Shapiro F, Waltzman R, Almadrones L, O’Flaherty C, O’Conner K, Venkatraman E, Barakat R, Curtin J, Brown C, Reich L, Wuest D, Norton L, Hoskins W, Spriggs DR: Phase II study of ‘dose-dense’ high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer. J Clin Oncol 1998;16:1852–1860.
11.
Weaver A, Wrigley E, Watson A, Chang J, Collins CD, Jenkins B, Gill C, Pettengell R, Dexter TM, Testa NG, Crowther D: A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide. Br J Cancer 1996;74:1821–1827.
12.
Wandt H, Birkmann J, Denzel T, Schäfer K, Schwab G, Pilz D, Egger H, Both A, Gallmeier WM: Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: A phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999;8:763–770.
13.
Pettengell R, Woll PJ, Thatcher N, Dexter TM, Testa NG: Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol 1995;1:148–156.
14.
Bokemeyer C, Franzke A, Hartmann JT, Schöber C, Arseniev L, Metzner B, Link H, Kanz L, Schmoll HJ: A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221–1227.
15.
Bokemeyer C, Kollmannsberger D, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C: First-line high dose chemotherapy compared with standard dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. J Clin Oncol 1999;17:3450–3456.
16.
Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N,I Camerlo J, Blaise D, Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D: Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin’s lymphoma. J Clin Oncol 1997;15:1722–1729.
17.
García-Rayo S, Pérez-Calvo J, Martín-Algarra S, Rebollo J, Samcam ME, Ordóñez JM, Snatistevan M, Cambeiro M, Brugarolas A: Alternating sequential intensive chemotherapy with stem cell support in metastatic breast cancer. Proc Am Soc Clin Oncol 1999;18:469.
18.
García-Rayo S, Pérez-Calvo J, Martin S, Martínez M, Ordóñez JM, Fernández N, Jurado M, Brugarolas A: A phase II study of high dose-intensity based chemotherapy with repeated stem cell support in advanced, relapsed and refractory ovarian cancer. Proc Am Soc Clin Oncol 2000;19:395a.
19.
Martínez-Aguillo, Pérez-Calvo J, Villafranca E, Santisteban M, García Rayo S, Martín Algarra S, Azinovic I, Brugarolas A: Feasibility of sequential dose-intensive chemotherapy with stem cell support in poor-prognosis Ewing`s sarcoma. Proc Am Soc Clin Oncol 2000;19:563a.
20.
Glück S, Ross AA, Layton TJ, Ostrander AB, Goldstein LC, Porter K, Ho AD: Decrease in tumor cell contamination and progenitor cell yield in leukapheresis products after consecutive cycles of chemotherapy for breast cancer treatment. Biol Blood Marrow Transplant 1997;6:316–323.
21.
Hryniuk W: Dose intensity; in Schilsky RL, Milano GA, Ratain MJ (eds): Principles of Antinooplastic Drug Development and Pharmacology. New York, Marcel Dekker, 1996, p 266.
22.
Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C: Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000;6:1360–1377.
23.
Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF: Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. J Clin Oncol 1999;7:2198–2207.
24.
Ross AA: Minimal residual disease in solid tumors: A review. J Hematother 1998;7:9–18.
25.
García-Conde J, Badía B, Benet I et al: Prognostic significance of contaminating tumor cells in BM and apheresis in breast cancer treated with autologous peripheral blood transplantation (Auto-PBT). Proc Am Soc Clin Oncol 1999;18:A352.
26.
Pecora AL, Preti RA, Lazarus HM et al: Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: Predictors and clinical outcomes (abstract 2952). Blood 1999;94(suppl 1):665a.
27.
Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: The results of 20 years of follow-up. N Engl J Med 1995;332:901–906.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.